<DOC>
	<DOC>NCT02313792</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety of palifermin on reducing mucositis for patients receiving autologous or allogeneic stem cell transplantation with supportive care.</brief_summary>
	<brief_title>Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<criteria>adequate organ function patients who will receive autologous stem cell transplantation patients who will receive allogeneic stem cell transplantation using myeloablative conditioning regimen presence of concomitant malignancy presence of active infection or oral mucositis prior to stem cell transplantation any conditions where the severity of oral mucositis cannot be evaluated</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hematopoietic stem cell transplantation</keyword>
	<keyword>Palifermin</keyword>
</DOC>